Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.44 +2.7%	$3.07	$2.07 ▼ $4.20	$107.91M	0.39	105,629 shs	82,598 shs
COYA Coya Therapeutics	$5.81 -2.5%	$5.80	$4.65 ▼ $10.24	$99.68M	0.26	73,464 shs	99,683 shs
CRBP Corbus Pharmaceuticals	$8.50 +0.5%	$7.98	$4.64 ▼ $61.90	$103.52M	3.05	334,437 shs	62,615 shs
MIRA MIRA Pharmaceuticals	$1.80 -10.9%	$1.31	$0.62 ▼ $5.01	$34.18M	1.72	2.34 million shs	2.33 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+2.69%	+9.55%	-3.10%	+26.47%	+9.21%
COYA Coya Therapeutics	-2.52%	-5.22%	+5.44%	+10.46%	-18.97%
CRBP Corbus Pharmaceuticals	+0.47%	+2.78%	+2.29%	+40.96%	-85.58%
MIRA MIRA Pharmaceuticals	-10.89%	+40.63%	+46.34%	+91.71%	+119.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.8479 of 5 stars	3.6	3.0	0.0	1.9	3.3	0.0
COYA Coya Therapeutics	1.8502 of 5 stars	3.5	3.0	0.0	0.0	0.8	0.0
CRBP Corbus Pharmaceuticals	4.7822 of 5 stars	4.6	3.0	4.7	2.7	2.5	0.6
MIRA MIRA Pharmaceuticals	2.5049 of 5 stars	3.7	3.0	0.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	161.63% Upside
COYA Coya Therapeutics	3.00	Buy	$16.50	183.99% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$50.88	498.53% Upside
MIRA MIRA Pharmaceuticals	3.33	Buy	$14.00	677.78% Upside

Current Analyst Ratings Breakdown

Latest MIRA, ANIX, COYA, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/12/2025	CRBP Corbus Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/7/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	CRBP Corbus Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$65.00 ➝ $58.00
5/7/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $56.00
5/7/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	527.63	N/A	N/A	$0.59 per share	5.83
COYA Coya Therapeutics	$3.55M	27.38	N/A	N/A	$2.37 per share	2.45
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$11.69 per share	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.22	N/A	N/A	N/A	N/A	-36.87%	-32.87%	8/5/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.51	N/A	N/A	N/A	N/A	-341.08%	-272.93%	8/12/2025 (Estimated)

Latest MIRA, ANIX, COYA, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	N/A	MIRA MIRA Pharmaceuticals	-$0.10	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.35	N/A	N/A	N/A	N/A	N/A
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/14/2025	Q1 2025	MIRA MIRA Pharmaceuticals	-$0.15	-$0.11	+$0.04	-$0.11	N/A	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
COYA Coya Therapeutics	N/A	8.84	8.84
CRBP Corbus Pharmaceuticals	N/A	11.82	11.82
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
COYA Coya Therapeutics	39.75%
CRBP Corbus Pharmaceuticals	64.64%
MIRA MIRA Pharmaceuticals	35.16%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
COYA Coya Therapeutics	12.00%
CRBP Corbus Pharmaceuticals	3.60%
MIRA MIRA Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
CRBP Corbus Pharmaceuticals	40	12.24 million	11.80 million	Optionable
MIRA MIRA Pharmaceuticals	2	16.92 million	15.80 million	Not Optionable

MIRA, ANIX, COYA, and CRBP Headlines

Recent News About These Companies

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for ...

July 11, 2025 | sacbee.comS

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

July 11, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Reports Promising SKNY-1 Preclinical Results

July 10, 2025 | tipranks.com

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 10, 2025 | uk.finance.yahoo.com

Mira Pharmaceuticals raises $2 million through at-the-market stock sale

July 9, 2025 | investing.com

MIRA Pharmaceuticals Raises $2M Through Stock Sale

July 8, 2025 | tipranks.com

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

July 3, 2025 | accessnewswire.comA

MIRA Pharmaceuticals: MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving ... - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

MIRA Data Shows Improved Weight Loss Potential

July 1, 2025 | finance.yahoo.com

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive ...

June 30, 2025 | palmbeachpost.comP

EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study

June 30, 2025 | finance.yahoo.com

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

June 30, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - El Paso Times

June 26, 2025 | elpasotimes.comE

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - The Des Moines Register

June 26, 2025 | desmoinesregister.comD

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking ... - The Columbus Dispatch

June 26, 2025 | dispatch.com

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - Milwaukee Journal Sentinel

June 26, 2025 | jsonline.comJ

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - Courier-Journal

June 26, 2025 | courier-journal.comC

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - azcentral.com

June 26, 2025 | azcentral.comA

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking ... - Asbury Park Press

June 26, 2025 | app.comA

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - The Journal News or lohud.com

June 26, 2025 | lohud.comL

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA, ANIX, COYA, and CRBP Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.44 +0.09 (+2.69%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.43 -0.01 (-0.29%)

As of 07/18/2025 07:56 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Coya Therapeutics NASDAQ:COYA

$5.81 -0.15 (-2.52%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.95 +0.14 (+2.48%)

As of 07/18/2025 05:54 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Corbus Pharmaceuticals NASDAQ:CRBP

$8.50 +0.04 (+0.47%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.69 +0.19 (+2.24%)

As of 07/18/2025 07:57 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.80 -0.22 (-10.89%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.81 +0.01 (+0.56%)

As of 07/18/2025 07:59 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time